Synthesize Bio
Facts
- HQ
- Seattle, WA, US
- Sectors
- Biotechnology Research
- Founded
- 2023
- Type
- Corporation Seattle business license
- Employees
- 21
- Registered name
- Synthesize Bio Seattle business license
- Stage
- Seed
- Founders
- Robert Bradley, PhD, Jeff Leek, PhD
AI House hosts Demo Day in Seattle with 25 startups pitching to investors flown in from Boston, New York, Colorado and the Bay Area
AI House hosted a demo day in Seattle where 25 early-stage startups—many outside the incubator’s portfolio—pitched to investors flown in from Boston, New York, Colorado, the Bay Area and other cities to increase outside capital for local founders. Organizers aimed to showcase diverse Seattle startups, from revenue-generating companies to ambitious technologists, and attracted both national and local venture investors.
Taylor Soper lists founders and startups who pitched at Demo Day, including Lightspeed AI, Vantari VR, Eidol AI and Hubble AI (YC S26)
A LinkedIn post by Taylor Soper lists founders who pitched at Demo Day, naming thirty individuals and teams along with their startups, including companies like Lightspeed AI, Vantari VR, Eidol AI, and Hubble AI (YC S26).
Seattle Startup Pauling.AI Uses AI to Cut Drug Discovery from Months to Weeks, Founded by Ex-Google Exec Javier Tordable in 2024
Seattle startup Pauling.AI uses AI to automate early drug discovery steps, reducing timelines from months to weeks and aiming to greatly increase new drug approvals. Founded in 2024 by former Google technical director Javier Tordable, the company offers a 'scientist-as-a-service' platform to assist researchers with computational chemistry and drug candidate modeling.
Susan Kaech Named Executive VP at Allen Institute; Arthur Valdez Joins Impinj Board; Jason Bennett Shifts to AWS VP Role
Susan Kaech joins the Allen Institute as executive VP of the Immunology Moonshot; Arthur Valdez Jr. joins Impinj's board; Jason Bennett transitions to VP of worldwide startups and venture capital at AWS. These leadership changes reflect strategic moves across bioscience, RFID technology, and cloud services sectors.
Fred Hutch-Led Synthesize Bio Raises $10M to Accelerate Drug Discovery Using AI Gene Expression Model
Seattle-based Synthesize Bio, led by Fred Hutchinson Cancer Center researchers, raised $10 million from Madrona to accelerate drug discovery using their AI model GEM-1, which predicts gene expression outcomes with lab-level accuracy. The startup aims to reduce drug development time and costs by simulating hypothetical lab experiments with generative genomics.
People
-
Matt McIlwain Board Member
